In the News

1855 News Items found
Press conference at MSK Nassau on March 10, 2021
In partnership with the Nassau County Department of Health, MSK Nassau will help equitably distribute COVID-19 vaccinations.
Research at MSK
This year, MSK joins the National Cancer Institute and the larger cancer community in commemorating the 50th anniversary of the signing of the National Cancer Act of 1971.
Memorial Sloan Kettering Chief Medical Epidemiologist Mini Kamboj
Women Leaders at MSK: Mini Kamboj
Mini Kamboj says encouragement from her family during her early years help mold her into the strong, self-possessed leader needed to guide MSK through the COVID-19 pandemic.
Damien Scogin is seen outdoors with his 9-year-old daughter, Jane. Damien is being treated at MSK’s Center for Young Onset Colorectal and Gastrointestinal Cancer, the first center in the world devoted to people under 50 with these types of cancer.
Learn more about the first facility in the world devoted to the specific needs of colorectal cancer patients under the age of 50.
Leukemia expert Anthony Mato
The first-ever clinical trial of a new kind of drug, called pirtobrutinib or LOXO-305, has shown promising results in a phase I/II study.
Developmental biologist Kathryn Anderson
Feature
Remembering Kathryn Anderson, the founding chair of the Developmental Biology Program in the Sloan Kettering Institute.
David Scheinberg and Lisa DeAngelis
MSK a Founding Member of Break Through Cancer
MSK is a founding member of Break Through Cancer, a newly launched foundation aimed at accelerating collaborative research, clinical trials, and cures for the deadliest cancers.
Physician-scientist Luc Morris
In the Lab
MSK researchers shed light on how the number of mutations in a tumor affect a patient’s response to immunotherapy drugs.
Carol Brown, MD
Gynecologic cancer surgeon Carol Brown featured in Crain's New York Business’ Notable Black Leaders and Executives list.
Dr. Robert Motzer speaks to a patient
MSK's Robert Motzer presented positive data from a phase III randomized study that assessed two different treatment combinations as first-line therapies that may benefit people with advanced kidney cancer.